Glutamate infusion associated with reduced rises of p‐Copeptin after coronary surgery: Substudy of GLUTAMICS II

Abstract

AbstractBackgroundGlutamate plays a key role for post‐ischaemic recovery of myocardial metabolism. According to post hoc analyses of the two GLUTAMICS trials, patients without diabetes benefit from glutamate with less myocardial dysfunction after coronary artery bypass surgery (CABG). Copeptin reflects activation of the Arginine Vasopressin system and is a reliable marker of heart failure but available studies in cardiac surgery are limited. We investigated whether glutamate infusion is associated with reduced postoperative rises of plasma Copeptin (p‐Copeptin) after CABG.MethodsA prespecified randomised double‐blind substudy of GLUTAMICS II. Patients had left ventricular ejection fraction ≤0.30 or EuroSCORE II ≥3.0 and underwent CABG ± valve procedure. Intravenous infusion of 0.125 M L‐glutamic acid or saline at 1.65 mL/kg/h was commenced 10–20 min before the release of the aortic cross‐clamp and then continued for another 150 min P‐Copeptin was measured preoperatively and postoperatively on day one (POD1) and day three. The primary endpoint was an increase in p‐Copeptin from the preoperative level to POD1. Postoperative stroke ≤24 h and mortality ≤30 days were safety outcomes.ResultsWe included 181 patients of whom 48% had diabetes. The incidence of postoperative mortality ≤30 days (0% vs. 2.1%; p = .50) and stroke ≤24 h (0% vs. 3.2%; p = .25) did not differ between the glutamate group and controls. P‐Copeptin increased postoperatively with the highest values recorded on POD1 without significant inter‐group differences. Among patients without diabetes, p‐Copeptin did not differ preoperatively but postoperative rise from preoperative level to POD1 was significantly reduced in the glutamate group (73 ± 66 vs. 115 ± 102 pmol/L; p = .02). P‐Copeptin was significantly lower in the Glutamate group on POD1 (p = .02) and POD 3 (p = .02).ConclusionsGlutamate did not reduce rises of p‐Copeptin significantly after moderate to high‐risk CABG. However, glutamate was associated with reduced rises of p‐Copeptin among patients without diabetes. These results agree with previous observations suggesting that glutamate mitigates myocardial dysfunction after CABG in patients without diabetes. Given the exploratory nature of these findings, they need to be confirmed in future studies.